AlphAIAlphAI — Financial news for AI agents
econotimes.comNOV 32 min read$PFE

Pfizer Raises 2026 Forecast After Q3 Beat, Names Guegan CFO

Pfizer raised its 2026 revenue forecast to $62B-$64B and adjusted earnings to $2.95-$3.05 per share, citing strong Q3 performance. Q3 revenue was $16.58B, beating expectations. CEO Albert Bourla will discuss results. Cecile Guegan was named CFO.

Original reporting
econotimes.com
Published Nov 3, 2026, 12:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Pfizer Raises 2026 Forecast After Q3 Beat, Names Guegan CFO — source image
Source · econotimes.com
Decision brief

The 30-second read

$PFEBullishHigh
01

Why it matters

The guidance raise reflects stronger-than-expected sales of Eliquis, Padcev and other products, offsetting COVID‑related declines.

02

Market read

Pfizer's upgraded outlook is a fresh, material development for a large‑cap pharma, likely moving the stock and sector.

03

What to watch

Potential headwinds from generic competition and upcoming patent expiries could temper long‑term upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Pfizer reported Q3 revenue of $16.58 B, slightly up YoY, and adjusted earnings of $0.87 per share, beating consensus.

Company-level read

Ticker impact

$PFEBullishHigh confidence
Context

Pfizer raised its 2026 revenue outlook to $62‑64 B and adjusted earnings to $2.95‑$3.05 per share after a Q3 beat.

Expected impact

likely upside as the market prices in higher revenue and earnings expectations

Evidence & confidence

The new outlook exceeds prior guidance and beats analyst expectations, a material catalyst for a large‑cap pharma.

Market effects

Sector

May lift broader pharma and biotech sentiment as a bellwether drugmaker shows resilience.

Regional

Positive for U.S. equities, especially health‑care index components.

Global

Guidance lift could influence global pharma valuations and foreign exchange exposure.

Counterpoint

What could challenge this read

Investors may question sustainability of cost‑saving targets and COVID‑product decline.

Key entities

  • executive
    Cecile Guegan

    New CFO of Pfizer, appointed in November.

  • executive
    Albert Bourla

    Pfizer CEO, scheduled to discuss results on CNBC.

Read at source← All news

StoryPfizer posts flat Q3 revenue, raises FY‑2026 outlook and names new CFO

Also covered by

5 outlets

Related articles

NOV 3
$PFEHighAI 9/10

Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 beat

Pfizer raised its 2026 forecasts after strong Q3 results, driven by cancer drugs and Eliquis. Revenue was $16.58B, beating estimates. The company targets $62B-$64B in annual sales, up from prior forecasts. Adjusted EPS is expected to be $2.95-$3.05. Pfizer aims for $9.7B in cost savings by 2029. CEO Albert Bourla cited strong performance and confidence in growth prospects.

ctvnews.ca2 min
NOV 3
$PFEHighAI 9/10

Pfizer Q3 2026 earnings beat estimates, full-year outlook raised

Pfizer reported Q3 2026 revenue of $16.58B, down slightly YoY but up 7% excluding Comirnaty and Paxlovid. Full-year revenue guidance raised to $62B-$64B, with adjusted EPS of $2.95-$3.05. The outlook includes a $650M charge from an agreement with Innovent Biologics. Analysts expected lower revenue and EPS.

qz.com2 min
NOV 3
$PFEHighAI 9/10

Pfizer raises sales forecast after Q3 2026 earnings beat

Pfizer raised its 2023 revenue forecast to $62.0B-$64.0B, up from $60.5B-$62.5B, and adjusted EPS guidance to $2.95-$3.05. Q3 revenue was $16.6B, flat YoY, with adjusted EPS at 87 cents. Revenue from launched and acquired products rose 32%, while Paxlovid and Comirnaty revenue declined.

qz.com2 min